Table 2.
Comparison of Survey Cohort to pre-COVID Study Cohort and National Data
| Variable | Present study N = 378 |
Pre-COVID cohorta N = 1743 |
P value | National datab,c N = 77 276b |
P value |
|---|---|---|---|---|---|
| Age, years, mean ± SD | 53 ± 13 | 51 ± 13 | <.01 | 48 ± 16b | <.01 |
| Sex, n (%) | … | … | .9 | … | <.01 |
| Female | 335 (89%) | 1541 (88%) | … | 58 213 (75%)b | … |
| Race, n (%) | … | … | <.01 | … | <.01 |
| White | 334 (90%) | 1654 (95%) | 63 479 (82%) b | … | |
| Cancer type (or NIFTP), n (%) | … | … | <.01 | … | <.01 |
| Papillary | 279 (74%) | 1313 (85%) | … | 64 625 (84%) b | … |
| Follicular | 26 (6.9%) | 97 (6.3%) | … | 8359 (11%) b | … |
| Medullary | 41 (10.9%) | 74 (4.8%) | … | 1685 (2.2%) b | … |
| Hürthle cell | 17 (4.5%) | 42 (2.7%) | … | … | … |
| NIFTP | 6 (1.6%) | 12 (0.8%) | … | … | … |
| Anaplastic | 1 (0.3%) | 7 (0.5%) | … | 975 (1.3%) b | … |
| Cancer stage, n (%) | … | … | .02 | … | <.01 |
| I | 101 (28%) | 522 (30%) | … | 25 580 (67%) b | … |
| II | 63 (18%) | 298 (17%) | … | 2870 (7.6%) b | … |
| III | 58 (16%) | 243 (14%) | … | 4562 (12%) b | … |
| IV | 60 (17%) | 199 (11%) | … | 3045 (8.0%) b | … |
| Unknown/not yet staged | 77 (13%) | 481 (28%) | … | 1881 (5.0%) b | … |
| Surgical therapy, n (%) | 366 (97%) | 1710 (98%) | .1 | … | … |
| Radioactive iodine, n (%) | 265 (70%) | 1366 (78%) | <.01 | 139 238 (50%)c | <.01 |
Abbreviation: NIFTP = Noninvasive follicular neoplasm with papillary-like nuclear features.
P values compared to present study cohort.
a
Goswami et al.6
b
Lim et al,4 Surveillance, Epidemiology, and End Results (SEER) data 1974-2013.
c
Orosco et al,11 SEER 1992-2009 and National Cancer Database 2004-2012, N = 276 558.